July 20, 2018


Yesterday the Advisory Council on the Misuse of Drugs (ACMD) has recommended that cannabis-derived medicinal products should be placed in Schedule 2 of the misuse of drugs regulations 2001, allowing them to be prescribed by clinicians.

The outcome was positive, albeit predictably cautious.

The Government has signalled that it is to concentrate on defining what constitutes cannabis derived medicine and clinical trials. 

Families 4 Access are going to work with a new medical cannabis institution that launches next week, and all Government pronouncements will be rigorously scrutinised.

We remain of the view that the priority now is to engage urgently with clinicians and their professional bodies to ensure that doctors and consultants are able to make informed decisions and that there is a comprehensive assessment of cannabis-based medicines that both meet quality standards and can be imported to the UK.

This all needs to happen in the public realm, not behind closed doors.

We are committed to engaging with the media and putting families first as we move into this new era.


ACMD Statement